The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
- The report reviews pipeline therapeutics for Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Alzheimer's Disease therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alzheimer's Disease
Companies Mentioned Include:
- AB Science SA
- AbbVie Inc
- AC Immune SA
- Accera, Inc.
- ALSP, Inc.
- Alzhyme Pty Ltd
- Alzinova AB
- AlzProtect SAS
- Amarantus Bioscience Holdings, Inc.
- Astellas Pharma Inc.
- Regenera Pharma Ltd.
- SignPath Pharma Inc
- Signum Biosciences, Inc.
- Simcere Pharmaceutical Group
- SK Biopharmaceuticals Co., Ltd.
- TechnoPhage SA
- Teijin Pharma Limited
- Treventis Corporation
- TyrNovo Ltd.
- UCB S.A.
- Varinel, Inc.
- Vaxine Pty Ltd
- Zhejiang Hisun Pharmaceutical Co., Ltd.
For more information about this report visit http://www.researchandmarkets.com/research/cvgwzx/alzheimers